report
result
studi
approv
drug
potenti
treatment
base
applic
variou
bioinformat
predict
method
drug
studi
includ
hydroxychloroquin
ivermectin
remdesivir
dmfo
result
indic
small
drug
molecul
select
bind
thermodynam
activ
residu
protein
surfac
prefer
hydrophob
activ
site
approach
restrict
virus
facilit
ration
drug
design
well
improv
understand
molecular
interact
gener
coronaviru
famili
includ
substanti
number
known
virus
caus
broad
rang
ill
common
cold
sever
diseas
like
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
etc
latest
worldwid
rapidli
spread
diseas
caus
new
member
viru
famili
diseas
origin
emerg
china
decemb
common
symptom
fever
cough
well
short
breath
sore
throat
headach
muscl
ach
nausea
diarrhea
case
initi
symptom
also
involv
unexplain
loss
tast
smell
viru
spread
direct
contact
person
person
quit
sever
patient
immun
system
weaken
preexist
condit
hypertens
diabet
mellitu
cardiovascular
diseas
viru
therefor
caus
tremend
number
death
world
manuscript
prepar
specif
vaccin
treatment
although
sever
effort
clinic
trial
underway
develop
vaccin
evalu
potenti
treatment
investig
may
take
mani
month
succeed
drug
repurpos
howev
may
offer
immedi
solut
consid
alreadi
approv
compound
potenti
treatment
facilit
task
undertook
compar
studi
analyz
predict
effect
variou
candid
drug
drug
studi
far
includ
hydroxyl
chloroquin
ivermectin
remdesivir
dmfo
see
tabl
supplementari
materi
mass
media
internet
even
profession
public
current
immers
controversi
debat
effect
lack
drug
treatment
avoid
get
involv
discuss
report
research
find
base
exist
bioinformat
predict
method
tool
method
develop
less
toxic
deriv
hydroxychloroquin
drug
use
prevent
treat
acut
attack
malaria
also
use
treat
discoid
system
lupu
erythematosu
rheumatoid
arthriti
patient
whose
symptom
improv
treatment
drug
subject
number
clinic
trial
worldwid
potenti
treatment
ivermectin
medic
use
treat
mani
variou
type
parasit
infest
includ
limit
head
lice
scabi
river
blind
onchocerciasi
strongyloidiasi
trichuriasi
ascariasi
lymphat
filariasi
depend
kind
treatment
taken
mouth
appli
skin
extern
infest
ivermectin
molecular
structur
rather
complex
made
set
macrocycl
lacton
isom
ivermectin
bind
glutamateg
chlorid
channel
increas
permeabl
chlorid
ion
drug
shown
inhibit
replic
vitro
current
subject
clinic
trial
potenti
treatment
remdesivir
medic
primarili
develop
treat
ebola
marburg
viru
diseas
drug
decreas
viral
rna
product
affect
function
viral
rnadepend
rna
polymeras
proofread
viral
exoribonucleas
exon
remdesivir
subject
clinic
trial
potenti
treatment
dmfo
medic
primari
use
treat
african
trypanosomiasi
sleep
sick
excess
facial
hair
women
specif
use
stage
sleep
sick
caus
b
gambiens
may
use
nifurtimox
use
inject
appli
skin
drug
prevent
bind
natur
product
ornithin
activ
site
ornithin
decarboxylas
find
record
drug
ever
tri
far
howev
sinc
halogen
organ
molecul
somehow
similar
activ
site
chloroquin
decid
studi
toward
treatment
analysi
chloroquin
bind
pattern
human
lysosom
protein
saposin
b
pdb
id
plasmodium
falciparum
lactat
dehydrogenas
pdb
id
shown
figur
reveal
chloroquin
bind
thermodynam
activ
site
recogn
sagnm
algorithm
mostli
hydrophob
activ
site
although
expos
solvent
bind
target
analysi
chloroquin
nondiscriminatori
bind
human
parasit
protein
may
offer
explan
effici
parasit
infect
well
offer
glimps
toxic
suggest
chloroquin
bind
protein
follow
pattern
attach
hydrophob
thermodynam
activ
residu
drug
ivermectin
bind
glutamateg
chlorid
channel
thu
increas
permeabl
chlorid
ion
analyz
ivermectin
bind
human
glycin
receptor
pdb
id
structur
besid
ivermectin
also
glycin
potenti
bound
glycin
receptor
receptor
pentam
analyz
bind
chain
analysi
shown
figur
reveal
three
compound
bind
thermodynam
activ
residu
highli
hydrophob
ivermectin
almost
bind
residu
hydrophob
mean
drug
well
seek
similar
site
surfac
protein
due
lack
protein
structur
remdesivir
follow
step
gao
collabor
analyz
bind
residu
hcv
rna
direct
rna
polymeras
pdb
id
sofosbuvir
compar
bind
residu
rna
direct
rna
polymeras
pdb
id
bind
residu
hcv
buri
deep
insid
polymeras
gener
thermodynam
activ
figur
explicitli
hydrophob
fig
structur
align
hcv
rna
polymeras
figur
show
share
structur
bind
pocket
also
reveal
signific
differ
analysi
thermodynam
activ
residu
rna
direct
rna
polymeras
reveal
differ
distribut
although
pocket
bound
activ
residu
figur
residu
abl
accommod
sofosbuvir
figur
similarli
hcv
polymeras
figur
c
overal
size
pocket
may
small
larger
compound
remdesivir
see
figur
supplementari
materi
analysi
suggest
remdesivir
bind
viru
rna
polymeras
alter
protein
configur
thu
prohibit
polymeras
function
analysi
show
interior
polymeras
attract
bind
spot
small
compound
although
distribut
activ
residu
differ
activ
residu
hcv
rna
polymeras
figur
show
thermodynam
activ
residu
recogn
bind
spot
cofactor
drug
eflornithin
prohibit
bind
natur
noncod
amino
acid
ornithin
activ
site
surfac
trypanosoma
brucei
ornithin
decarboxylas
odc
pdb
id
therefor
bind
drug
follow
bind
pattern
ornithin
figur
show
sagnm
algorithm
accur
detect
bind
site
ornithin
geneticin
aminoglycosid
antibiot
contrari
chloroquin
compound
bind
prefer
hydrophil
site
surfac
odc
appli
treat
drug
eflornithin
bind
similar
site
surfac
protein
hydrophob
thermodynam
activ
analysi
spike
glycoprotein
receptor
bind
domain
rbd
sar
pdb
id
pdb
id
reveal
signific
differ
two
protein
sar
rbd
chain
thermodynam
activ
residu
direct
contact
human
antibodi
figur
rbd
structur
antibodi
segment
rbd
miss
analysi
reveal
thermodynam
activ
residu
partial
hidden
orient
away
antibodi
bind
region
sar
see
figur
f
may
indic
differ
receptor
bind
mechan
differ
bind
affin
also
better
abil
avoid
antibodi
produc
immun
system
model
miss
residu
rbd
program
model
see
figur
sagnm
algorithm
suggest
bind
antibodi
residu
posit
almost
opposit
bind
residu
sar
spike
glycoprotein
see
figur
suggest
potenti
mechan
avoid
immun
system
antibodi
may
difficulti
access
residu
howev
model
equilibr
molecular
dynam
therefor
previou
conclus
tent
analysi
thermodynam
activ
residu
sar
monom
figur
reveal
thermodynam
activ
site
attract
bind
spot
glycan
form
glycan
shield
suggest
assist
immun
evas
similarli
envelop
trimer
thermodynam
activ
residu
therefor
use
target
area
drug
aim
removingdisrupt
viru
glycan
shield
residu
particularli
hydrophob
target
drug
bind
hydrophil
patch
first
sever
global
pandem
caus
coronaviru
guarante
last
therefor
need
develop
effect
effici
treatment
also
design
set
protocol
address
futur
potenti
pandem
manuscript
present
strategi
recogn
drug
bind
residu
viral
protein
analyz
four
current
approv
drug
chloroquin
ivermectin
remdesivir
via
sobosfuvir
eflornithin
result
indic
small
drug
like
compound
preferenti
bind
thermodynam
activ
residu
drug
seek
activ
patch
protein
surfac
mostli
hydrophob
chloroquin
ivermectin
prefer
hydrophil
patch
sofosbuvir
eflornithin
may
impli
design
drug
cocktail
virus
drug
bind
hydrophob
hydrophil
patch
combin
avoid
conflict
analysi
use
viralparasit
well
human
protein
analysi
show
thermodynam
activ
residu
exist
human
nonhuman
proteinsenzym
drug
bind
indiscrimin
regardless
origin
inform
may
help
access
drug
toxic
gener
bind
spot
predict
approach
access
bioinformat
tool
shape
complementar
bind
affin
properti
well
procedur
develop
fast
effect
analyz
protein
much
faster
comput
demand
molecular
dynam
simul
requir
protein
structur
advantag
effici
also
abil
suggest
gener
bind
pattern
drug
protein
use
filter
bind
area
protein
surfac
thu
facilit
preclin
stage
drug
design
aim
analyz
present
avail
structur
protein
predict
bind
pattern
describ
four
drug
well
human
receptor
predict
bind
residu
protein
appli
self
adjust
interpret
gaussian
network
model
sagnm
structur
align
visual
analys
perform
program
chimera
vmd
miss
segment
protein
structur
model
program
model
focus
studi
pdb
structur
list
drug
present
ligand
chloroquin
analyz
structur
saposin
pdb
id
ivermect
analyz
bind
pattern
drug
human
glycin
receptor
pdb
id
remdesivir
analyz
bind
pattern
drug
sofosbuvir
known
protein
structur
remdesivir
ligand
sofosbuvir
alreadi
analyz
light
remdesivir
sofosbuvir
bind
pattern
rna
direct
rna
polymeras
analyz
hepat
c
viru
hcv
rna
direct
rna
polymeras
pdb
id
rna
direct
rna
polymeras
pdb
id
analyz
structur
trypanosoma
brucei
ornithin
decarboxylas
odc
dornithin
bound
pdb
id
bind
activ
site
odc
inhibit
ornithin
bind
also
analyz
spike
glycoprotein
sar
human
neutral
antibodi
pdb
id
spike
glycoprotein
pdb
id
